Analyspodden - bolag & aktier med DNB Carnegie

Analyspodden is a finance podcast centered on companies, shares, and the work of turning business detail into an investable view. Its conversations are deliberately practical. Episodes tend to begin with a company, sector, or investment case and then widen into the questions that matter for shareholders: margins, markets, customer mix, capital allocation, regulation, liquidity, and timing. The show gives operating businesses room to explain themselves. Systemair becomes a discussion about air quality, regional access, factories, EBIT goals, and acquisitions that strengthen routes to market. Qualisys becomes a way to talk about high-precision motion capture, clean data, camera platforms, software, competition, and technological barriers without leaning on a patent story. Life science episodes move more carefully. Elicera Therapeutics and Lytix Biofarma are discussed through immuno-oncology, clinical validation, study data, approval markets, partnerships, funding paths, and the unusually high risk that sits inside biotech cases. Sector updates can be equally granular. Contract manufacturers are framed through H2 2025 development, 2026 expectations, medtech, electrification, defense, customer concentration, and customer exposure. The show also makes space for investor process. Henrik Söderberg’s appearance turns toward small-cap funds, flows, platform distribution, liquidity risk, and what happens when larger institutions move money in or out. The editorial feel is sober but not remote. Speakers ask clarifying questions, circle back to definitions, and restate the central thesis from several angles until the listener can see both the company story and the investment constraints around it. It is not a hype vehicle. The strongest episodes work because they keep translating technical detail into the plain investor question underneath: what is the business advantage, how durable is it, and what could still go wrong?